236 related articles for article (PubMed ID: 32188703)
1. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
[TBL] [Abstract][Full Text] [Related]
2. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
3. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
4. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
6. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
7. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
8. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
[TBL] [Abstract][Full Text] [Related]
9. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
12. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. MEK Inhibition Remodels the Immune Landscape of Mutant
Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Wang X; Yang X; Zhang C; Wang Y; Cheng T; Duan L; Tong Z; Tan S; Zhang H; Saw PE; Gu Y; Wang J; Zhang Y; Shang L; Liu Y; Jiang S; Yan B; Li R; Yang Y; Yu J; Chen Y; Gao GF; Ye Q; Gao S
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6640-6650. PubMed ID: 32161124
[TBL] [Abstract][Full Text] [Related]
16. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
17. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
18. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
20. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
